large

Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules

Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3Achieves 10x improvement in…

1 month ago

Unison Supports Large Federal Agency Program with Bulk Contract Modifications to Comply with New RFO Guidance

MCLEAN, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Unison, the leading provider of AI acquisition and contract writing software for…

3 months ago

Hettich India recognised among the Top 50 India’s Best Workplaces in Manufacturing 2026 – Large Category

MUMBAI, India, Feb. 2, 2026 /PRNewswire/ -- Hettich India has been recognised among the Top 50 India's Best Workplaces™ in…

4 months ago

BIO-key and Visualforma Awarded Contract to Secure Digital Identities for Large Municipality in Portugal

HOLMDEL, N.J. and FARO, Portugal, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a leading provider of…

4 months ago

Strong Q3 Performance: Sequential Revenue Growth of 0.6% in CC, Large Deal Wins of $4.8 billion

Revenue Guidance for FY 26 revised to 3.0%-3.5%BENGALURU, India, Jan. 14, 2026 /PRNewswire/ -- Infosys (NSE: INFY), (BSE: INFY), (NYSE: INFY),…

4 months ago

Online Casino Real Money No Deposit Bonus Get $5 No Deposit Bonus + Large Welcome Bonus By BC Poker

New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) --  Players searching for an online casino real money no deposit…

5 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

5 months ago

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

July 29, 2025 09:01 ET  | Source: Windtree Therapeutics Investors choose to redeem or convert the majority of Series C…

10 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

11 months ago